ZA200701187B - Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma ; method for detection and test system - Google Patents
Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma ; method for detection and test system Download PDFInfo
- Publication number
- ZA200701187B ZA200701187B ZA200701187A ZA200701187A ZA200701187B ZA 200701187 B ZA200701187 B ZA 200701187B ZA 200701187 A ZA200701187 A ZA 200701187A ZA 200701187 A ZA200701187 A ZA 200701187A ZA 200701187 B ZA200701187 B ZA 200701187B
- Authority
- ZA
- South Africa
- Prior art keywords
- transthyretin
- level
- colorectal
- sample material
- colorectal carcinoma
- Prior art date
Links
- 108010071690 Prealbumin Proteins 0.000 title claims description 129
- 102000009190 Transthyretin Human genes 0.000 title claims description 128
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims description 77
- 206010009944 Colon cancer Diseases 0.000 title claims description 76
- 201000010989 colorectal carcinoma Diseases 0.000 title claims description 71
- 201000002758 colorectal adenoma Diseases 0.000 title claims description 70
- 238000001514 detection method Methods 0.000 title claims description 46
- 238000000034 method Methods 0.000 title claims description 42
- 239000000090 biomarker Substances 0.000 title claims description 27
- 238000012360 testing method Methods 0.000 title claims description 27
- 239000000523 sample Substances 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 210000002966 serum Anatomy 0.000 claims description 28
- 239000007787 solid Substances 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 16
- 210000001124 body fluid Anatomy 0.000 claims description 14
- 239000010839 body fluid Substances 0.000 claims description 14
- 230000007423 decrease Effects 0.000 claims description 13
- 230000035945 sensitivity Effects 0.000 claims description 13
- 238000004949 mass spectrometry Methods 0.000 claims description 11
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims description 9
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 5
- 239000002853 nucleic acid probe Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 238000011002 quantification Methods 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims description 2
- 210000000416 exudates and transudate Anatomy 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 235000020256 human milk Nutrition 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 description 12
- 206010001233 Adenoma benign Diseases 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 208000003200 Adenoma Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 238000002052 colonoscopy Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 4
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 208000004804 Adenomatous Polyps Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 2
- 241000147041 Guaiacum officinale Species 0.000 description 2
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000009541 flexible sigmoidoscopy Methods 0.000 description 2
- 229940091561 guaiac Drugs 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- 238000001698 laser desorption ionisation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 241000565118 Cordylophora caspia Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 1
- 101710097927 Retinal-binding protein Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100029290 Transthyretin Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010921 in-depth analysis Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102000024458 retinal binding proteins Human genes 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Description
USE OF TRANSTHYRETIN AS A BIOMARKER FOR COLORECTAL ADENOMA
AND/OR CARCINOMA; METHOD FOR DETECTION AND TEST SYSTEM
The present invention relates to the field of detection of colorectal adenoma and/or colorectal carcinoma.
Colorectal carcinoma is the third most frequently diagnosed carcinoma and the second leading cause of carcinoma death in Europe and in the United States. In 1996, an estimated 133 500 new cases of colorectal carcinoma were diagnosed and approximately 54 900 people died of this disease in the United States. The incidence of colorectal carcinoma is increasing, while the mortality rate of colorectal carcinoma ~ is decreasing. Incidence of colorectal carcinoma increases with age, beginning at around 40 years of age, and it is higher for men than for women (60.4 for men versus 40.9 for women, per 100 000 per year).
In most patients, development of colorectal carcinoma follows a multistep progression from premalignant adenoma to invasive malignancies that have the propensity for metastasis. There is evidence that reduction in colorectal carcinoma morbidity and mortality can be achieved through detection and treatment of early- stage colorectal carcinomas and identification and removal of colorectal adenomatous polypes, which are the precursors of colorectal carcinoma.
Colorectal screening tests have been shown to achieve accurate detection of early stage colorectal carcinoma at its precursors, i. e. adenomatous polypes and/or flat neoplastic areas. Several tests are available as options for colorectal carcinoma screening. The screening tests encompass faecal occult blood testing (FOBT), flexible sigmoidoscopy, FOBT combined with flexible sigmoidoscopy and colonoscopy. The various screening tests differ from each other regarding performance, effectiveness, possible screening frequency, test complications, costs and acceptance of patient.
Screening by the faecal occult blood test is currently considered to be the optimal screening strategy in terms of cost-effectiveness. Occult blood in stool can be detected by chemical agents such as guaiac, through hemeporphyrin or immunological methods. The guaiac slide test Hemoccult (Il) available from
SmithKline Diagnostics is most widely used.
Various technical factors affect its clinical performance. Hemoccult has about 50 % sensitivity for colorectal carcinomas and about 98 % specificity, however, the sensitivity is low for polypes, at around 10 % (Simon JB. (1998) Gastroenterologist 6.66-78. Review). Another important drawback of occult blood screening is the poor accuracy of prediction, only 10 % of positive reactions prove to be due to colorectal carcinoma (Simon JB. (1998) Gastroenterologist 6:66-78. Review; Mandel JS et al. " (1999) J. Natl. Cancer Inst. 91:434-437; Hardcastle JD et al. (1996) Lancet 348:1472-1477; Kronborg O et al. (1996) Lancet 348:1467-71; Winawer SJ et al. (1997) Gastroenterology 112:594-642; Fletcher RH (1998) N. Engl. J. Med. 338:1153-1154).
Moreover, a faecal occult blood test does only provide results after progression of the disease to a certain stage. It would be desirable to have a test system allowing the detection of colorectal adenoma and/or colorectal carcinoma at an earlier point in time.
More recently developed immunological tests generally have high sensitivity, however, a poor specificity which remains an important problem. Other methods, such as genetic testings of stool samples for KRAS oncogenes and for p53 protein, are not yet cost-effective (Calistri D et al. (2003) Clin. Gastroenterol. Hepatol. 1:377- 383; Schoen RE (2002) Nat. Rev. Cancer 2:65-70).
Endoscopy (Kavanagh AM (1998) Cancer Causes Control 9:455-462), using either the flexible sigmoidoscope or the colonoscope (Lieberman DA (1997) Gastroenterol.
Clin. N. Am. 26: 71-83), is the most definitive means of detection, but has limitations.
The false negative rate for flat neoplastic lesions has been recognized and remains to be high (Kudo S (1997) Gastrointest. Endosc. Clin. N. Am. 7:87-98.). Colonoscopy permits examination of the colon with a low false negative rate for polypoid lesions of at least 10 mm in diameter. For this reason, the intervals allowed before re- examination are relatively long after a negative assessment (up to ten years) or up to five years after polypectomy.
However, patient compliance with such recommendation for reexamination after colonoscopy is poor. Moreover, a colonoscopy is costly and cumbersome. In view of the high costs of a generalized examination and the limited acceptance of a colonoscopy by the population this examination method has a limited application.
Isolated tissue samples, which are collected, can be tested for colorectal carcinoma and its precursors, colorectal adenoma, by various methods. DE 197 11 111A discloses a method using an in vitro determination of intraepithelial colon bacteria, components and reaction products thereof. Another method using HERG gene expression in tissue samples is disclosed in DE 102 24 534.
An object of the invention is to provide means allowing an early detection of colon adenoma and/or colon carcinoma.
It is a further object to provide a biomarker which can be used in the detection of colorectal adenoma and/or carcinoma.
Another object of the present invention is to provide a test system for detecting colorectal adenoma or carcinoma which is cost effective and can be widely used.
Moreover, the test system should be easy to handle and more convenient for the individual to be examined for colorectal adenoma and/or carcinoma.
The objects underlying the present invention are solved by the use of transthyretin as a biomarker for the detection of colorectal adenoma and/or colorectal carcinoma in an individual. The detection can be carried out in vivo and in vitro. Pursuant to a preferred embodiment, the detection is carried out in vitro.
The objects are further solved by a method for detecting colorectal adenoma and/or colorectal carcinoma comprising the steps: - : a) providing an isolated sample material which has been taken from an individual, b) determining the level of transthyretin in said isolated sample material, c) comparing the determined level of transthyretin with a reference value.
The objects are further solved by a method for discriminating between colorectal adenoma and colorectal carcinoma comprising the steps: a) providing an isolated sample material which has been taken from an individual, b) determining the level of transthyretin in said isolated sample material, c) comparing the determined level of transthyretin with a reference value.
The objects are also solved by a method for monitoring the course of colorectal adenoma and/or colorectal carcinoma and/or the treatment of colorectal adenoma and/or colorectal carcinoma comprising the steps: a) providing an isolated sample material which has been taken from an individual, b) determining the level of transthyretin in said isolated sample material, c) comparing the determined level of transthyretin with a reference value.
The objects are solved as well by providing a test system for detecting colorectal adenoma and/or colorectal carcinoma in an individual comprising: a) an antibody or a receptor which binds to an epitope of transthyretin, b) a solid support which supports said antibody or receptor, c) a reagent for detecting the binding of said epitope of transthyretin to said antibody or receptor.
The objects are furthermore solved by the provision of an array comprising detection molecules for detecting of colorectal adenoma and/or colorectal carcinoma in an individual comprising as detection molecule: a) a nucleic acid probe immobilized to a solid support for binding to and detecting of MRNA encoding transthyretin, or : b) an antibody immobilized to a solid support for binding to and detecting of an epitope of transthyretin, or c) a receptor immobilized to a solid support for binding to and detecting of an epitope of transthyretin, wherein preferably each different amounts of detection molecules are immobilized to the solid support to increase the accuracy of the quantification.
Preferred embodiments are specified in dependent claims.
Pursuant to the present invention the term “biomarker” is meant to designate a protein or protein fragment which is indicative for the incidence of the colorectal adenoma and/or colorectal carcinoma. That means the “biomarker” is used as a detection agent or detection molecule.
The term “individual” or “individuals” is meant to designate a mammal. Preferably, the mammal is a human being such as a patient.
The term “healthy individual” or “healthy individuals” is meant to designate individual(s) not diseased of colorectal adenoma and/or colorectal carcinoma. That is to say, the term "healthy individual(s)” is used only in respect of the pathological condition of colorectal adenoma and/or colorectal carcinoma and does not exclude the individual to suffer from diseases other than colorectal adenoma and/or colorectal carcinoma.
The term “transthyretin” as used in the present invention also comprises truncated transthyretin, fragments of transthyretin, mutated transthyretin, or modified transthyretin. The modification of “transthyretin can be due to enzymatic or chemical modification. Moreover, the term “transthyretin” is also used to designate monomeric or multimeric forms of transthyretin. For example, the term “transthyretin” especially covers the monomeric protein chain usually being part of the homotetrameric protein transthyretin. :
The term “epitope” is meant to designate any structural element of transthyretin allowing the specific binding of an antibody, an antibody fragment, a protein or peptide structure or a receptor.
The process of isolating the sample material is not part of the invention. That is to say, the methods of the present invention are carried out with sample material such as a body fluid which already has been isolated. It is for example possible, to store the sample material to be tested in a freezer and to carry out the methods of the present invention at an appropriate point in time after thawing the respective sample material.
It has been surprisingly discovered by the present inventors that the protein transthyretin can be used as a biomarker for the detection of colorectal adenoma and/or carcinoma.
Transthyretin is also designated as prealbumin. Transthyretin is a tetrameric protein having a molecular weight of about 54 kDa that is synthesized mainly in the liver.
Transthyretin is composed of four protein chains of about 14 kDa which can be identical. That is to say, transthyretin can be regarded as a homo tetrameric protein.
It functions primarily as a binding protein for thyroxin, and as a carrier protein for retinal binding protein, which in turn is the transport protein for vitamin A (Schussler,
GC Thyroid. (2000), 10:372; Hamilton, JA and Benson, MD Cell of Life Sci. (2001) 58:1491-1521).
Transthyretin is also reported to form complexes with amyloid B-protein.
Aggregation of amyloid B-protein is associated with deposition of amyloid in the brain, which is a pathological feature of Alzheimer's disease.
;
Transthyretin has been further described as an indicator of the nutritional status, since serum levels of transthyretin decline with inadequate protein intake and during acute or chronic inflammation. In addition, transthyretin is suitable for monitoring the nutritional status because of its short half live of only 2-3 days (Pleban
WE, Conn. Med. (1989) 53: 405-407; Bernstein LH and Ingenbleek Y, Clin. Chem.
Lab. Med. (2002) 40:1344-1348).
WO 02/059621 discloses reagents which regulate transthyretin and reagents which bind to transthyretin gene products, thereby playing a role in preventing, ameliorating or correcting obesity and related dysfunctions.
It has been shown by SELDI (surface enhanced laser desorption/ionisation) analysis that the monomeric transthyretin protein chain occurs in human plasma or serum at least in two variants having a molecular weight of 13,736 Da and 13,858 Da, respectively.
The different molecular weights are thought to be due to various post-translational modifications such as truncation, cysteinylation, and/or glutationylation. Cysteinylated transthyretin has a molecular weight of about 13,871 + 11 Da, and the glutationylated transthyretin has a molecular weight of about 14,069 + 5 Da.
WO 03/001182 discloses the detection and isolation of homocysteinylated transthyretin from a biological fluid and its use as a marker for diagnosis of homocysteinemia, hyperhomocysteinemia and diseases associated therewith.
In some studies, transthyretin has been discussed as diagnostic marker for carcinoma. Suresh et al. (J. Clin. Pathol. (1991) 44: 573-575) described transthyretin as a useful marker in bronchopulmonary carcinoid tumors since 75 % of the carcinoid tumors were positive for transthyretin. In another study, transthyretin was discussed as prognostic marker in epithelial ovarian carcinoma (Mabhlck et al,
Gynecol. Obstet. Invest. (1994) 37: 135-140).
Amended sheet 7 February 2008
The inventors have now surprisingly found that the level of transthyretin in a body fluid is correlated with the incidence of colorectal adenoma and/or carcinoma in an individual. :
Pursuant to the present invention, transthyretin can be measured in body fluids such as blood, blood plasma, blood serum, bone marrow, stool, synovial fluid, lymphatic fluid, cerebrospinal fluid, sputum, urine, mother milk, sperm, exudate and mixtures thereof.
Preferably, the body fluid has been isolated before carrying out the methods of the present invention. The methods of the invention are preferably carried out in vitro by a technician in a laboratory.
According to a preferred embodiment of the invention, transthyretin is measured in blood plasma or blood serum. Blood serum can be easily obtained by taking blood from an individual to be medically examined and separating the supernatant from the clotted blood.
The level of transthyretin in the body fluid, preferably blood serum, decreases with progressive formation of colorectal adenoma. The colorectal adenoma is a benign neoplasma which may become malign. When developing colorectal cancer from benign colorectal adenom, the level of transthyretin in body fluids, preferably blood serum, further decreases.
After transformation of colorectal adenoma into colorectal cancer, the pathological condition of the afflicted individual can be further exacerbated by formation of metastasis.
The present invention provides an early stage biomarker which allows to detect the neoplastic disease at an early and still benign stage. The early detection enables the physician to timely remove the colorectal adenoma and to dramatically increase the chance of the individual to survive.
Moreover, the present invention allows to monitor the level of transthyretin in a body fluid such as blood serum over an extended period of time, such as years.
The long term monitoring allows to differentiate between colorectal adenoma and colorectal carcinoma. The level of transthyretin can be routinely checked, for example, once or twice a year. If a decrease of the level of transthyretin is detected this can be indicative for colorectal adenoma. A further decrease of the level of transthyretin can then be indicative for the transformation into malign colorectal carcinoma.
Moreover, the course of the disease and/or the treatment can be monitored. If the level of transthyretin further decreases, for example after removal of the colorectal adenoma, this can be indicative for exacerbation of the pathological condition.
That means, the level of transthyretin is a valuable clinical parameter for detecting and/or monitoring of colorectal adenoma and/or colorectal carcinoma. The level of transthyretin in body fluids decreases very early after incidence of colorectal adenoma. Therefore, transthyretin or the level of transthyretin is an important clinical parameter to allow an early diagnosis and, consequently, an early treatment of the disease.
The method of the invention for detection of colorectal adenoma and/or colorectal carcinoma comprises the step of providing an isolated sample material which has been taken from an individual, then determining the level! of transthyretin in the isolated sample material, and finally comparing the determined level of transthyretin with a reference value.
The reference value can be calculated as the average level of transthyretin determined in a plurality of isolated samples of healthy individuals. This reference value can be established as a range to be considered as normal meaning that the person is healthy. A fall below this range can then be indicative for the pathological condition of colorectal adenoma and/or colorectal carcinoma. This range of reference value can be established by taking a statistically relevant number of body fluid samples, such as serum samples, of healthy individuals as it is done for any other medical parameter range such as, e.g., blood sugar.
In an another embodiment of the present invention, the reference value can be an individual reference value calculated as the average level of transthyretin determined in a plurality of isolated samples taken from the individual over a period of time.
When monitoring the transthyretin level over an extended period of time, such as months or years, it is possible to establish an individual average level. The transthyretin level can be measured, for example, from the same blood serum sample when measuring blood sugar and can be used to establish an individual calibration curve allowing to specifically detect any individual decrease of the level of transthyretin.
In another aspect the present invention further provides a test system for detecting colorectal adenoma and/or colorectal carcinoma in an individual. The test system is based either on the specificity of an antibody or a receptor to bind to an epitope or a suitable structural element of transthyretin or a fragment of transthyretin. A receptor can be any structure able to bind specifically to transthyretin. The receptor can be, for example, an antibody fragment such as an Fab or an F(ab’). fragment or any other protein or peptide structure being able to specifically bind to transthyretin.
The antibody, antibody fragment or receptor is bound to a solid support such as, e.g., a plastic surface or beads to allow binding and detection of transthyretin. For example, a conventional microtiter plate can be used as a plastic surface. The detection of the binding of transthyretin can be effected, for example, by using a secondary antibody labelled with a detectable group. The detectable group can be, for example, a radioactive isotop or an enzyme like horseradish peroxidase or alkaline phosphatase detectable by adding a suitable substrate to produce, for example, a colour or a fluorescence signal.
The test system can be an immunoassay such as an enzyme-linked immunosorbentassay (ELISA) or an radio immunoassay (RIA). However, any other immunological test system using the specificity of antibodies or fragments of antibodies can be used such as Western blotting or immuno precipitation.
The present invention also provides an array comprising detection molecules for detecting colorectal adenoma and/or colorectal carcinoma in an individual, wherein the detection molecule can be a nucleic acid probe immobilized on a solid support for binding to and detecting of MRNA encoding transthyretin, fragments, mutations, variants or derivatives thereof, or an antibody immobilized on a solid support for binding to and detecting of an epitope of transthyretin, or a receptor immobilized on a solid support for binding to and detecting of an epitope of transthyretin.
The nucleic acid probe can be any natural occurring or synthetic oligonucleotide, as well as cDNA, cRNA and the like.
The described array can be used in a test system according to the invention. The array can be either a micro array or a macro array. The support can be a polymeric material such as nylon or plastic or an inorganic material such as silicon, for example a silicon wafer, or ceramic. Pursuant to a preferred embodiment, glass (SiOz) is used as solid support material. The glass can be a glass slide or glass chip. Pursuant to another embodiment of the invention the glass substrate has an atomically flat surface.
For example, the array can be comprised of immobilized nucleic acid probes able to specifically bind to mRNA of transthyretin being present in a body fluid such as serum. Another preferred embodiment is to produce cDNA by reverse transcription of transthyretin mRNA and to specifically detect the amount of respective cDNA with said array. The array technology is known to the skilled person. A quantification of the measured mRNA or cDNA, respectively, can be effected by comparison of the measured values with a standard or calibration curve of known amounts of transthyretin mRNA or cDNA.
Preferably, different amounts of detection molecules are immobilized each on the solid support to allow an accurate quantification of the level of transthyretin.
Pursuant to another embodiment of the invention, the level of transthyretin is determined by mass spectroscopy.
Mass spectroscopy allows to specifically detect transthyretin or the monomeric protein chains thereof via its molecular weight and to quantify the amount of transthyretin very easily.
Transthyretin is normally a homotetramer comprising four protein chains having each a molecular weight of about 14 kDa.
Using mass spectroscopy the inventors have detected several variants of the transthyretin protein chains having a molecular weight of inter alia 13,776 Da, 13,884 Da or 14,103 Da.
The inventors have found out that especially the level of molecular variants of transthyretin having a molecular weight of 13,776 Da and 13,884 Da is decreased in a body fluid such as serum in case of incidence of colorectal adenoma and/or colorectal carcinoma.
Any suitable ionization method in the field of mass spectroscopy known in the art can be employed to ionize the transthyretin molecule, fragments, mutations, variants or derivatives thereof. The ionization methods comprise electron impact (El), chemical ionization (Cl), field ionization (FDI), electrospray ionization (ESI), laser desorption ionization (LDI), matrix assisted laser desorption ionization (MALDI) and surface enhanced laser desorption ionization (SELDI).
Amended sheet 7 February 2008
Any suitable detection method in field of mass spectroscopy known in the art can be employed to determine the molecular mass of transthyretin, fragments, mutations, variants or derivatives thereof. The detection methods comprise quadrupol mass spectroscopy (QMS), fourier transform mass spectroscopy (FT-MS) and time-of-flight mass spectroscopy (TOF-MS).
Preferably, the mass spectroscopy is a surface enhanced laser desorption ionization- time of flight-mass spectroscopy (SELDI-TOF-MS). Before carrying out a SELDI-
TOF-MS, the transthyretin in the isolated sample is preferably immobilized on a chip or solid support with an activated surface. The activated surface comprises preferably immobilized anti-transthyretin antibodies such as, for example, rabbit polyclonal anti-transthyretin antibodies. After binding of the transthyretin to the antibodies, a time-of-flight analysis in a SELDI-TOF mass spectrometer is carried out, which delivers intensity signals for determination of the transthyretin level.
Moreover, mass spectroscopy allows to simultaneously detect other proteins which can have a relevance with respect to the detection of colorectal adenoma and/or colorectal cancer.
In another embodiment of the present invention the sensitivity and/or specificity of the detection of colorectal adenoma and/or colorectal carcinoma is enhanced by detection of another protein in combination with transthyretin.
Another biomarker for colorectal adenoma and/or colorectal carcinoma, the level of which can be determined in addition to the level of transthyretin, comprises a protein or polypeptide having a molecular weight of 8,960 Da. The level of said 8,960 Da protein or polypeptide in a sample material has been found to be increased in colorectal adenoma and/or colorectal carcinoma when compared to the level of this protein or polypeptide in samples isolated from healthy individuals.
Amended sheet 7 February 2008
Therefore, it is preferred to determine the level of said protein having a molecular weight of 8960 + 9 Da in addition to the level of transthyretin in a body fluid suchas ~~ serum by mass spectroscopy. The mass spectroscopy is the method of choice to detect and quantify the level of said 8960 + 9 Da protein.
In another embodiment of the present invention the sensitivity and/or specificity of the detection of colorectal adenoma and/or colorectal carcinoma is enhanced by detection of CEA (carcinoembryonic antigen) and/or CA 18-9 in combination with transthyretin. CEA and CA 19-9 were both analyzed as response indicators and prognostic factors in advanced colorectal carcinoma.
In a further embodiment of the present invention the sensitivity and/or specificity of the detection of colorectal adenoma and/or colorectal carcinoma is enhanced by detection of CA15-3, CA-125 and/or Her-2/neu in combination with transthyretin.
CA15-3 is an oncofetal antigen, which is expressed by several carcinomas, and is often measured with other tumor markers. Both CA15-3 and CA-125 are prognostic indicators, mainly for breast cancer, but also in addition to visceral metastases. The amplification of Her-2/neu in breast carcinoma is associated with poor prognosis, short disease-free interval and short survival time. Little is known up to now about the starting point of amplification and the progress of Her-2/neu up to now.
The methods of the present invention can be carried out in combination with other diagnostic methods for detection of colorectal adenoma and/or colorectal carcinoma to increase the overall sensitivity and/or specificity.
Preferably, the methods of the present invention are carried out as an early detection and/or monitoring method. If the results of the methods of the present invention should indicate the incidence of colorectal adenoma and/or colorectal adenoma, further examinations such as colonoscopy or a faecal occult blood testing (FOBT) should be carried out.
The following polyclonal anti-transthyretin antibodies can be used when practicing the invention: PC 066 available from The Binding Site Ltd., Birmingham, England and
A 0002, available from DAKO, Hamburg, Germany.
The following figures and example are given for illustrative purposes only. The invention is not to be construed to be limited to the following examples.
Fig. 1 shows a schematic diagram for fractionating and profiling of serum samples.
Fig. 2 shows a SELDI-TOF profile.
Fig. 3 shows a differention of healthy individuals from adenoma/carcinoma individuals.
Fig. 4 shows SELDI-TOF protein profiles of serum fractions from three different individuals
Fig. 5 shows SELDI immunoaffinity capture of transthyretin and its potential derivatives.
Fig. 6 shows immunoprecipitation with an anti-transthyretin antibody.
Unless otherwise stated all methods were carried out following the protocol of the manufacturer of the analytical systems.
Serum collection and serum fractionation
° = LH] o 2 © ac hd 2 < 0 [e3} ° S ® ~ = : © 2 [03] = Lo 5 8 = g , © : cg 2 3 2 6 0 = > © = c g cE 8 2 sg 9 zg 5c £ 8 ¢ 8 5 gg i T 2348 = 5 8 5 83 g £9 8 , 8 g 82g 2 & c 8 2 c 5 Sc 2 3 o> 322 7B € 8 vw 2 © Tc & © vw € 3} = Tp «© oO TT DO ®@ 3 5S > 9 9 vg 22 = 2 £8 8 3 5 ° co 2 o 8 TY £5 EF » 22 0 § £0 bk - 2 3 8 ° TT @ < ESD zo LQ ao x gg 8 5 £ g L&C vw a oD © 5 6 4 9 ° 5 Ey 0g BE
E §oeg = g 8 acc £ E888: Sg 2732%T, 5 2 9 5 © ® 8 8 8 2 8 Sg ®& € 3 3 5 t 2 @ c 3 c . £ Bb = 5 2 - © ® 0 Bn . oo & § ®@ © oO I 8 25%%9 8 Sg £08 22T8 gl wT 4 Ep 3 5% © © = © > 3 £39 S 2 ot aa g2eg=23 2 £ = £E 9 = Fs 2 og 5 £ o = £ 5S 5E8 oE 5s 3 a JE Sao Sf 52 sh 2% £ Ep
I) a vv 0 9 = © [LI c 5 0 X ££ = 5 FZ £ ¢g 2 © 2 ® GQ = 5 8 a ¢ © 8 “5 2 a ® 9 a @ © 5 SG 2 582 3% »~ ® o 3 & 3a oD © 2 n° c 25% § oO w= 2 J 3) 2 5 2 w 2 re ° co 5 = 0 © Ec 50 290 8 3 © [5] c 5 © 3 w Cc = 0 uw = = Wu @ w= ££ == 4 = = oOo E -_ [0 2 c =n 5 cE [7 PR > © £ oo © 0 © £ 2 [] § 2 8 ao © = 8 ® = 8 £ 4 © ao 9 8 o > 58 2c td £ & © 9 a = £ > 0 © = oc 32 c= - ® = c e [) n= © O ec 2 dL 5 2 5 © > £ 2 2% 050g 2 2 38 88 32 EF re Od Et B® ® 5 2 Eg ££ Oo To ££ 3p ©» £ = wD OC gon T= o ER — 3] 2 ga © 2 0 ‘n = c © 0 wo 8 € = 0 cw 2 0 2 8 = o£ % 6 Eg = © “ @ E 2 5 sc oo 3 - tr = = cs ¥ §g © «= o © 2 = t © 8 cc ££ 2 © 0 o § © ®o c = 3 > a c © 2 2
TT @ © © £ oO £ ss © © oe OMmMDBT OT OE =v Fey c P= 2 2 a w— ES T= §@ = [5] =e > xX j= ET £E L, 6 © FZ Ec 8 8 8 » 2 © 2 88 , 82 £ wn ZF = 0 0 nw FF © © a Gg = vw 5 9 © So = 2 » ¢ o a2 o 2 Q o = > 2 £ © o a = 3 ct £ = ct o tc E o£ c « fa = 2 = cc £ a9 r= Qo = e od A © Oo = ee © [4] 0 o£ © 0 a Bb ov % ¢ kt va =I NS = SE cc 3 9 0g a 0 3 OQ 50 c © © 5) g © 5 2 TQ © = g a ® zY 853% SOB GE £ Ct o £ 3 co a = a 3 @ c 2 = oo OB SOG EE ® og © 5 a o © 5 © o 3 wo © a 6 5 cg 0 0 @ = © c = 2 3 ad 3 EE ND aN 8 8 2 8X §8 uu & = 2 2£F 21 le} w © OS — © hol p=] oS oc 95 QQ M0 = = =
E © 0 wv Bb 5 8 5 5 © Ee c 0 § 55 2 <2 Gv © a 6 = £8 oc © © = ov Cc oc ® E Tt 8 © = q@ vu © £ >a 5 € 6 = © Ww wn O c o w EE oo c ® E 2c Cc ® a 5 ro) = 8 £8Tc F232 ts g = £ §2sEge £58c3°% = R] 0 » 5 @© = = © = -
Z £ 3 2 3 2 2 5 5 & © = 9 = © 2 2 28 © ® , £ 2 gq E
E = zg&gs ts 2gf§ 22e gfofss S228 8x3 £ o 6c 4 7 £ [SS o 2 = So & 6 L 8 © « © E = a & « g & ~ 3 £ = ~ a o> 5 9 £E £E = © D0 2s nu 0 = 5] 2 o ND —- 2B E 5 Q@ 8 © Oo £ © © ¢£ .. J a E a © 9 a © o I) ® © A E So © © g = > cs wv 2 3 ES $389 Sg F358 Eg 28583f SsEegoel o 4 o = = oO © Oo
I) = g§ £ © = = QO 5 £ 5 0 oo © © 92 »7 Cc 2 = © g§ £ 7) O® 6 + £ Oo =2 0 £ 0 Ui a a w» © 3 aw 8 fa ® 8 Ek E cation exchange array with carboxylate functionality. Two fractions that gave the highest number of evaluable peaks were selected (fraction 1, fraction 4) for a profiling approach on a chip that showed the lowest data variability (CM10 array).
These two fractions were measured in all three groups using Ciphergen
ProteinChip® Array CM 10.
Chiphergen ProteinChip® array preparation and SELDI-TOF-MS analysis
CM10 protein arrays were processed in a bioprocessor (Ciphergen Biosystems,
Inc.) according to the protocol of manufacturer. Chips were equilibrated with CM10 binding buffer (Ciphergen Biosystems, Inc.) for 2x5 minutes and were subsequently incubated with the serum fractions which had been diluted 1:10 in CM10 binding buffer. After 45 minutes the unbound material was removed and the chips were washed 3 times with CM10 binding buffer and 2 times with water. After drying at room temperature for 10 minutes, 2 applications of 0.05 M sinapinic acid (1.0 pl) were added and the chips were analyzed with the Ciphergen Protein ChipReader (model PBSII).
The Protein ChipReader is a time-of-flight mass spectrometer. The mass values and signal intensities for the detected proteins are transferred to a software, which is supplied by Ciphergen for further in-depth analysis by the ProteinChip Data
Analysis Program and Biomarker Wizard Program.
To minimize data variability, measurement was performed within two days using samples from all patient groups randomly distributed on the chips. As a standard control for normalization, pooled normal serum was used parallel to all measurements.
The mass spectra of proteins were generated by using an average of 195 laser shots at a laser intensity of 185. The detector was run at a sensitivity of 7. For data acquisition, the detection size range was set between 2,000 and 40,000 Da.
Amended sheet 7 February 2008
The laser was focused at 10,000 Da. The data were analyzed with the ProteinChip
Data Analysis Program (version 3.1, Ciphergen Biosystems) and with the Biomarker
Wizard Program (version 3.1, Ciphergen Biosystems). The peak intensities were normalized to the total ion current.
Results
In this experiment, differentially expressed proteins between serum from non- carcinoma patients (Group 1) and serum from patients with colorectal adenoma (Group 2) and colorectal carcinoma (Group 3) were identified. As shown in Table 1, six peaks could be identified in fraction 1 that showed the mean-values of intensity of highly significant differences (p < 0.0000001) between healthy patients (non-cancer patients), colorectal adenoma patients and colorectal carcinoma patients. As shown in Table 2, fraction 4 provided an additional set of potential biomarkers that differed significantly between the three groups (p < 0.0000001).
Table 1: Biomarkers selected after processing of fraction 1 of each serum sample on Ciphergen chips. The p-values were generated with nonparametric tests from the Biomarker Wizzard application. N gives the transthyretin level for ‘healthy’ patients,
A for colorectal adenoma patients and Ca for colorectal carcinoma patients. StDev is the standard deviation of the measurement.
Table 2: Biomarkers selected after processing of fraction 4 of each serum sample on Ciphergen chips. The p-values were generated with nonparametric tests
Amended sheet 7 February 2008 from the Biomarker Wizzard application. N gives the transthyretin level for ‘healthy’ patients, A for colorectal adenoma patients and Ca for colorectal carcinoma patients.
StDev is the standard deviation of the measurement.
StDev N StDev Ca 6850 |<0.0000001 [1.10 [029 _ [0.69 [021 _ [081 _ [0.33 6385 | <0.0000001 7055 [<0.0000001 13770 | <0.0000001 13900 _|<0.0000001 14160 | <0.0000001 4975 |<0.0000001 6645 |<0.0000001 14060 | <0.0000001 6950 |<0.0000001 51485 | <0.0000001 22330 |<0.0000001 5765 _|<0.0000001 28100 0.000001 5915 [<0.0000001 7415 |<0.0000001
Several proteins were tested as single biomarkers and in combination with other markers using the Biomarker Pattern Software. One protein with a molecular weight of 13,770 Da (p13,770) was found to discriminate between adenomal/carcinoma patients and healthy controls giving a sensitivity of 75% and a specificity of 90 %.
Fig. 2 shows a SELDI profile demonstrating the biomarker. Fig. 3.shows the discrimination of healthy patients from adenoma/carcinoma patients in a scatter plot. The intensities of the biomarker having a molecular weight of 13,770 Da (p13,370) are significantly lower in the serum of adenoma/cancer patients than in healthy patients.
Fig. 4 shows SELDI-TOF protein profiles of serum fraction no. 4 from healthy, adenoma patients and cancer patients. As can be seen the intensity of the
Amended sheet 7 February 2008 p13,370 peak decreases significantly from healthy patients over colorectal adenoma patients to colorectal cancer patients.
In combination with a second marker protein (MW 8,960 Da, fraction no. 1), separation of healthy patients from adenoma/carcinoma patients was significantly improved. 30 non-adenoma/carcinoma (healthy) patients, 20 of 29 colorectal adenoma patients as well as 20 of 28 colorectal carcinoma patients were correctly separated. With this combination, a sensitivity of 70% and a specificity of 100% were achieved.
Identification of transthyretin
Using immunoaffinity capture and immunoprecipitation tests, the 13,770 Da protein was identified as transthyretin.
Protein Chip immunoaffinity capture of transthyretin
The immunoaffinity capture was performed using a Protein G Array (Ciphergen
Biosystems, Inc.) following the manufacturer's protocol. A rabbit polyclonal anti- transthyretin antibody A0002 (Dako, Hamburg, Germany), diluted to a concentration of 0.2 pg/pl in PBS. 2 pl per spot were pipetted on the array and subsequently incubated for 24 h at 4°C in a humidified chamber. Unbound antibody was removed by washing with washing buffer (0.5% (v/v) triton X-100 in
PBS. After drying, the array was inserted into a bioprocessor (Ciphergen
Biosystems, Inc.) for sample incubation. 2 pl of serum fractions containing high and low amounts of the 13,770 Da protein (colorectal adenoma/carcinoma patients versus healthy patients) were added to the chip and incubated for 1 h at room temperature on a horizontal shaker. After washing with PBS and HEPES buffer the array was air dried for 10 minutes and 0.6 pl saturated sinapinic acid matrix was added to each spot. The array was measured using the following parameters: the laser intensity was set to 185, the sensitivity to 7. The detection
Amended sheet 7 February 2008 size range was set to between 200 and 200,000 Da, the laser was focused at 10 000 Da.
After binding to the antibody coated array, four protein peaks of different molecular weight (approximately 13,761 Da, 13,914 Da, 14,102 Da and 14,292 Da) have been identified, suggesting that transthyretin occurs in different molecular variants.
Figure 5 shows a comparison of the signal intensities between a healthy patient and a carcinoma patient.
Finally, an immunoprecipitation was carried out. 50 pl of serum of fraction 4 from different patients were incubated with 15 pl (6,75 ug) of the polyclonal antibody against transthyretin for 2 hours at 4 °C. A negative control was performed in the same way without antibody. 50 pl of protein A/G agarose (Pierce, Rockford, IL) was added and incubated at 4 °C over night. After centrifugation at 3300 xg, the supernatants were removed and stored separately. The pellet was resuspended in 20 yl buffer (9M urea, 2 % Chaps, 50 mM Tris-HCI, pH 9) to detach the proteins from the protein A/G-agarose. Precipitate as well as supernatant were diluted 1:10 in CM10 binding buffer. Three proteins with different molecular weights (13,776 Da, 13,884 Da, 14,103 Da) were immunoprecipitated with an anti-transthyretin antibody. From Figur 6 it can be seen that in the supernatant, the amount of two variants (13,776 Da and 13,884 Da) was significantly reduced, whereas the amount of the variant with the highest molecular weight (14,103 Da) remained unchanged.
This shows that the transthyretin protein chains having a molecular weight of about 13,776 Da and about 13,884 Da are important biomarkers for the detection of colorectal adenoma and/or colorectal carcinoma.
Amended sheet 7 February 2008
Claims (28)
1. A method for detecting colorectal adenoma and/or colorectal carcinoma comprising the steps: a) providing an isolated sample material which has been taken from an individual, b) determining the level of transthyretin in said isolated sample material, c) comparing the determined level of transthyretin with a reference value.
2. A method for discriminating between colorectal adenoma and colorectal carcinoma comprising the steps: a) providing an isolated sample material which has been taken from an individual, b) determining the level of transthyretin in said isolated sample material, c) comparing the determined level of transthyretin with a reference value.
3. A method for monitoring the course of colorectal adenoma and/or colorectal carcinoma and/or the treatment of colorectal adenoma and/or colorectal carcinoma comprising the steps: a) providing an isolated sample material which has been taken from an individual, b) determining the level of transthyretin in said isolated sample material, c) comparing the determined level of transthyretin with a reference value.
4. The method according to any one of claims 1 to 3, wherein the level of transthyretin of said sample material is decreased compared to a sample material of a healthy individual.
5. The method according to any one of claims 2 to 4, wherein a first decrease of the level of transthyretin in a first sample material is indicative for colorectal adenoma and wherein a second decrease of the level of transthyretin in a second sample material, isolated from said individual at a later point in time than the first sample material, is indicative for colorectal carcinoma, with the proviso that said second decrease is stronger than said first decrease.
6. The method according to any one of claims 1 to 5, wherein the reference value is calculated as the average level of transthyretin determined in a piurality of isolated samples of healthy individuals.
7. The method according to any one of claims 1 to 5, wherein the reference value is an individual reference value calculated as the average level of transthyretin determined in a plurality of isolated samples taken from said individual over a period of time.
8. The method according to any one of claims 1 to 7, wherein the transthyretin is composed of one or four protein chains, which can be identical or different from each other.
9. The method according to any one of claims 1 to 8, wherein the transthyretin is truncated, modified and/or mutated.
10. The method according to any one of claims 1 to 9, wherein the isolated sample material is a body fluid.
11. The method according to claim 10, wherein the body fluid is selected from the group consisting of blood, blood plasma, serum, bone marrow, stool, synovial fluid, lymphatic fluid, cerebro spinal fluid, sputum, urine, mother milk, sperm, exudate and mixtures thereof.
12. The method according to any one of the preceding claims, wherein the level of transthyretin in said sample material is determined by mass spectroscopy.
13. The method according to any one of claims 1 to 12, wherein the level of carcinoembryonic antigen (CEA) in said sample material is additionally determined and wherein the level of said carcinoembryonic antigen (CEA) in said sample material is increased by colorectal adenoma and/or colorectal carcinoma.
14. The method according to any one of claims 1 to 13, wherein the level of CA 19-9 in said sample material is additionally determined and wherein the level of said CA 19-9 in said sample material is increased by colorectal adenoma and/or colorectal carcinoma.
15. The method according to any one of claim 1 to 14, wherein the level of a protein or polypeptide having a molecular weight of 8360 + 9 Da is additionally determined and wherein the level of said 8960 £ 9 Da protein or polypeptide in said sample material is increased by colorectal adenoma and/or colorectal carcinoma.
16. The method according to any one of claims 1 to 11, wherein the level of transthyretin in said sample material is determined by an immunoassay, preferably by ELISA or RIA.
17. The method according to any one of claims 1 to 11, wherein the level of transthyretin in said sample material is determined by determining the level of mRNA encoding transthyretin in said sample material.
18. The method according to any one of the preceding claims, wherein the method is carried out in combination with other diagnostic methods for colorectal adenoma and/or colorectal carcinoma to increase sensitivity and/or specificity.
19. A use of transthyretin as a biomarker for a detection of colorectal adenoma and/or colorectal carcinoma in an individual.
20. The use according to claim 19 for an early detection of colorectal adenoma and/or colorectal carcinoma.
21. The use according to claim 19 or 20 wherein transthyretin is truncated, modified and/ or mutated.
22. The use according to any one of claims 19 to 21, in combination with one or more further biomarkers for colorectal adenoma and/or colorectal carcinoma to increase sensitivity and/or specificity.
23. The use according to claim 22, wherein said at least one further biomarker comprise carcinoembryonic antigen (CEA), the level of which in said sample material is increased by colorectal adenoma and/or colorectal carcinoma.
24. The use according to claim 22, wherein said at least one further biomarker comprise CA 19-9, the level of which in said sample material is increased by colorectal adenoma and/or colorectal carcinoma.
25. The use according to claim 22, wherein said at least one further biomarker has a molecular weight of 8960 + 9 Da, the level of which in said sample material is increased by colorectal adenoma and/or colorectal carcinoma.
26. A test system for detecting colorectal adenoma and/or colorectal carcinoma in an individual comprising: a) an antibody or a receptor which binds to an epitope of transthyretin, b) a solid support which supports said antibody or receptor, c) a reagent for detecting the binding of said epitope of transthyretin to said antibody or receptor.
27. A test system pursuant to claim 26, wherein said test system comprises one or more antibodies or receptors for detection of one or more further biomarkers for colorectal adenoma and/or colorectal carcinoma.
28. An array comprising detection molecules for detecting of colorectal adenoma : - and/or colorectal carcinoma in an individual comprising as detection molecule: : a) a nucleic acid probe immobilized to a solid support for binding to and detecting of MRNA encoding transthyretin, or : b) an antibody immobilized to a solid support for binding to and detecting of an epitope of transthyretin, or c) a receptor immobilized to a solid support for binding to and detecting of an epitope of transthyretin, wherein preferably each different amounts of detection molecules are immobilized to the solid support to increase the accuracy of the quantification.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200701187A ZA200701187B (en) | 2004-08-13 | 2004-08-13 | Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma ; method for detection and test system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200701187A ZA200701187B (en) | 2004-08-13 | 2004-08-13 | Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma ; method for detection and test system |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200701187B true ZA200701187B (en) | 2008-05-28 |
Family
ID=40635716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200701187A ZA200701187B (en) | 2004-08-13 | 2004-08-13 | Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma ; method for detection and test system |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200701187B (en) |
-
2004
- 2004-08-13 ZA ZA200701187A patent/ZA200701187B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL181132A (en) | Use of transthyretin as a biomarker for colorectal adenoma, method for detection and test system | |
KR102130855B1 (en) | Method for detecting nucleosomes containing histone variants | |
EP2375254A1 (en) | Free NGAL as a biomarker for cancer | |
EP3839513B1 (en) | Use of dna-transcription factor complexes for cancer detection | |
WO2016195051A1 (en) | Plasma biomarker panel for diagnosing pancreatic cancer | |
WO2009061412A1 (en) | Methods for detecting or monitoring cancer using lpe as a marker | |
ZA200701187B (en) | Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma ; method for detection and test system | |
KR20070051327A (en) | Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system | |
ZA200801353B (en) | Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma ; method for detection and test system | |
WO2010017331A1 (en) | Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease | |
TWI757285B (en) | Method for detection of a cancer | |
WO2023230584A1 (en) | Methods and systems for risk stratification and management of bladder cancer | |
van Winden | Use of proteomics for the early diagnosis fo breast cancer |